Apitegromab

Apitegromab (SRK-015) is a fully human monoclonal antibody developed to treat spinal muscular atrophy. It works by binding to and inhibiting promyostatin, a precursor to myostatin, which limits the size of skeletal muscle tissue, as well as inactive myostatin. It does not bind to active myostatin, activin A, active BMP9/10 or TGFβ1 that all operate on the activin type 2 receptors.^[1][2][3]

Apitegromab

Monoclonal antibody
Type	?
Target	Promyostatin
Clinical data
Other names	SRK-015
Identifiers
CAS Number	2278276-46-1
UNII	UZ54216N0Y